Singapore markets closed

Cyclerion Therapeutics, Inc. (CYCN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
0.8807-0.0693 (-7.29%)
At close: 03:59PM EST
0.9100 +0.01 (+1.11%)
Pre-market: 08:27AM EST

Cyclerion Therapeutics, Inc.

245 First Street
18th Floor
Cambridge, MA 02142
United States
857 327 8778

Full-time employees32

Key executives

NameTitlePayExercisedYear born
Dr. Peter M. Hecht Ph.D.CEO & Director108.22kN/A1964
Ms. Cheryl GaultChief Operating Officer513.43kN/A1980
Ms. Anjeza GjinoCFO & Corp. Sec.N/AN/A1983
Dr. Todd Milne Ph.D.Sr. VP of External InnovationN/AN/AN/A
Ms. Jessica RennekampAssociate Director of Corp. CommunicationsN/AN/AN/A
Mr. Christopher Winrow Ph.D.Sr. Director of Clinical Devel. & Neuroscience Program LeadN/AN/AN/A
Ms. Jennifer Chickering Ph.D.Sr. Director of Clinical StrategyN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Cyclerion Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.